Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE) (CT-PLAQUE)

May 14, 2026 updated by: The University of Hong Kong
The study aims at determining if the presence of adverse plaque features identified from the CT angiogram can help determine prognosis and guide treatment options.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

22000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Hong Kong
      • Hong Kong, Hong Kong
        • The University of Hong Kong

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

28000

Description

Inclusion Criteria:

  • Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment
  • If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.

Exclusion Criteria:

  • Patient who did not undergo cardiac CT scan due to inability to undergo cardiac CT scanning, kidney failure (serum creatinine >250 μmol/L or estimated glomerular filtration rate <30 mL/min), major allergy to contrast.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patient who is ≥ 18 years old presented with chest pain and has undergone CTA before treatment
Diagnostic test: CTCA

Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment

- If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death and all-cause death
Time Frame: 5 years after CTCA examinations
5 years after CTCA examinations

Secondary Outcome Measures

Outcome Measure
Time Frame
Total plaque (mm³) to predict cardiac events
Time Frame: 5 years after CTCA examinations
5 years after CTCA examinations
Calcified plaque (mm³) to predict cardiac events
Time Frame: 5 years after CTCA examinations
5 years after CTCA examinations
Non-calcified plaque (mm³) to predict cardiac events
Time Frame: 5 years after CTCA examinations
5 years after CTCA examinations
CT-FFR to predict cardiac events
Time Frame: 5 years after CTCA examinations
5 years after CTCA examinations

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 29, 2020

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

July 7, 2025

First Submitted That Met QC Criteria

October 1, 2025

First Posted (Actual)

October 8, 2025

Study Record Updates

Last Update Posted (Actual)

May 19, 2026

Last Update Submitted That Met QC Criteria

May 14, 2026

Last Verified

June 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UW20-057

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on FFR-CT

Clinical Trials on CTCA

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe